Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 345-351

  Gjertsen, Bjørn T ^a   Logothetis, Christopher J ^a   McDonnell, Timothy J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Bax; bcl 2; p53; Prostate cancer

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW;

EID: 0032779935     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006170332301     Document Type: Review

References (62)

1. Bruckheimer EM, Gjertsen BT, McDonnell TJ: Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol (in press)
2. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-5, 1991
3. Cardillo M, Berchem G, Tarkington MA, Krajewski S, Krajewski M, Reed JC, Tehan T, Ortega L, Lage J, Gelmann EP: Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J Urol 158: 212-6, 1997
4. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang, JM, Hait, WN: The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4: 1393-403, 1998
5. Keshgegian AA, Johnston E, Cnaan A: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110: 443-9, 1998
6. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW: p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51: 346-51, 1998
7. Beham AW, Brisbay S, Sarkiss M, Tu SM, von Eschenbach AC, McDonnell TJ: Molecular correlates of bcl-2 enhanced growth following androgen-ablation in prostate carcinoma cell in vivo. Int J Mol Med 1; 953-959, 1998
8. Zhang X, Chen MW, Ng A, Ng PY, Lee C, Rubin M, Olsson CA, Buttyan R: Abnormal prostate development in C3(1)- bcl-2 transgenic mice. prostate 32; 16-26, 1997
9. Bruckheimer EM, Brisbay SM, Gingrich JR, Greenberg NM, McDonnell TJ: Characterization of probasin bcl-2 transgenic mice and the contribution of bcl-2 to prostate cancer progression. Proc Amer Assoc Cancer Res 39; 466, 1998
10. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, McDonnell TJ: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93: 147-55, 1995
11. Westin P, Lo P, Marin MC, Fernandez A, Sarkiss M, Tu S-M, Brisbay SM, von Eschenbach AC, McDonnell TJ: Bcl-2 confers androgen independence in androgen sensitive prostate carcinoma. Int J Oncol 10: 113-118, 1997
12. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-9, 1997
13. Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT, Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630-3, 1994
14. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151: 492-5, 1994
15. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-69, 1993.
16. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-73, 1993
17. Mottaz AE, Markwalder R, Fey MF, Klima I, Merz VW, Thalmann GN, Ball RK, Studer UE: Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. prostate 31: 209-15, 1997
18. Eastham JA, Stapleton AMF, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC: Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1: 1111-1118, 1995
19. Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA: Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 25: 92-7, 1994
20. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr TW, Neal DE: p53 expression and clinical outcome in prostate cancer. Br J Urol 72: 778-81, 1993
21. Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, Hartmann J, Jonas U: The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 34: 679-86, 1998
22. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC: bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 74: 1258-62, 1996
23. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S: Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4: 839-43, 1998
24. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-19, 1997
25. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-16, 1998
26. Jost CA, Marin MC, Kaelin WG, Jr: p73 is a human p53-related protein that can induce apoptosis. Nature 389: 191-4, 1997
27. Zhu J, Jiang J, Zhou W, Chen X: The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 58: 5061-5, 1998
28. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A: Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 58: 2076-7, 1998
29. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer [see comments]. J Urol 157: 569-74, 1997
30. Marin MC, Hsu B, Meyn RE, Donehower LA, el-Naggar AK, McDonnell TJ: Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9: 3107-12, 1994
31. Hori M, Nogami T, Itabashi M, Yoshimi F, Ono H, Koizumi S: Expression of Bcl-2 in human breast cancer correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis. Patholnt 47: 757-62, 1997
32. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-28, 1995
33. Subramanian T, Tarodi B, Chinnadurai G: p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: suppression by E1B 19K and Bcl-2 proteins. Cell Growth Differ 6: 131-7, 1995
34. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-39, 1994
35. Beham A, Marin MC, Fernandez A, HerrMarin J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ: Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 15: 2767-72, 1997
36. Beham A, Vogel M, McDonnell TJ, St. Farkas A, Fürst A, Jauch KW: Apoptosis after genotoxic damage is enhanced by Taxol induced phosphorylation of bcl-2 and correlates with nuclear import of p53. Proc Am Assoc Cancer Res, 1998
37. Ding HF, Fisher DE: Mechanisms of p53-mediated apoptosis. Crit Rev Oncog 9: 83-98, 1998
38. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RS: Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16: 2345-9, 1998
39. Iwadate Y, Tagawa M, Fujimolo S, Hirose M, Namba H, Sueyoshi K, Sakiyama S, Yamaura A: Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br J Cancer 77: 547-51, 1998
40. Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, Lorsen AK, Paillerets BB, Chouaib S: Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 15: 2817-26, 1997
41. Zhan Q, Alamo I, Yu K, Boise LH, Cherney B, Tosato G, O'Connor PM, Fornace AJ, Jr: The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function. Oncogene 13: 2287-93, 1996
42. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-4, 1996
43. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, et al.: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151-5, 1995
44. Srivastava S, Katayose D, Tong YA, Craig CR, McLeod DG, Moul JW, Cowan KH, Seth P: Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 46: 843-8, 1995
45. Yang C, Cirielli C, Capogrossi MC, Passaniti A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55: 4210-3, 1995
46. Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW: Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 7: 1683-91, 1996
47. Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth P, Srivastava S: Inhibition of the growth of preestablished subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int J Cancer 71: 377-82, 1997
48. 8. Schumacher G, Bruckheimer EM, Beham A, Honda T, Roth JA, McDonnell TJ: Adenoviral transfer of wild-type p53 leads to growth inhibition and apoptosis in human prostate cancer cell lines which is inhibited when bcl-2 is overexpressed. Proc 17th Intl Cancer Congress (in press)
49. Nielsen LL, Lipari P, Dell J, Gumani M, Hajian G: Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4: 835-46, 1998
50. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW: Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J Urol 158: 636-41, 1997
51. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-9, 1995
52. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, el-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump OS, Shin DM, Walsh GL: Gene therapy for non-small cell lung cancer: a preliminary report of a phase 1 trial of adenoviral p53 gene replacement. Semin Oncol 25: 33-7, 1998
53. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 2221-32, 1998
54. Haldar S, Chintapalli J, Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-5, 1996
55. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL: Involvement of microtubules in the regulation of bcl-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18: 3509-17, 1998
56. Gjertsen BT, Doskeland SO: Protein phosphorylation in apoptosis. Biochim Biophys Acta 1269: 187-99, 1995
57. Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Shrivastav M, Chung T, Stadler WM, Rinker-Schaeffer CW: Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential. Clin Cancer Res 4: 2391-8, 1998
58. Dorai T, Olsson CA, Katz AE, Buttyan R: Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone- refractory human prostate cancer. Prostate 32: 246-58, 1997
59. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137-41, 1997
60. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT: Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 58: 2134-40, 1998
61. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4: 327-32, 1993
62. Gazzaniga P, Gradilone A, Vertillo R, Gandini O, Silvestri I, Napolitano M, Albonici L, Vincenzoni A, Gullucci M, Frati L, Agliano AM: Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 69: 100-4, 1996